Well Differentiated Liposarcoma
NCI Definition: A locally aggressive malignant neoplasm composed of mature adipocytes showing cell size variation and nuclear atypia. It is often associated with the presence of hyperchromatic multinucleated stromal cells, and varying numbers of lipoblasts. There are three histologic subtypes, sclerosing, inflammatory, and spindle cell liposarcoma. These tumors do not usually metastasize unless they undergo dedifferentiation. 
Well differentiated liposarcomas most frequently harbor alterations in MDM2, CDK4, GLI1, SDHC, and DDR2 .
MDM2 Amplification, CDK4 Amplification, GLI1 Amplification, SDHC Amplification, and DDR2 Amplification are the most common alterations in well differentiated liposarcoma .
There are 2 clinical trials for well differentiated liposarcoma, of which 2 are open and 0 are completed or closed. Of the trials that contain well differentiated liposarcoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
Atezolizumab, cobimetinib, and sitravatinib are the most common interventions in well differentiated liposarcoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.